Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

May 23, 2000; 54 (10) Special Article

Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors

Report of the Quality Standards Subcommittee of the American Academy of Neurology

M.J. Glantz, B.F. Cole, P.A. Forsyth, L.D. Recht, P.Y. Wen, M.C. Chamberlain, S.A. Grossman, J.G. Cairncross
First published May 23, 2000, DOI: https://doi.org/10.1212/WNL.54.10.1886
M.J. Glantz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B.F. Cole
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.A. Forsyth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L.D. Recht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.Y. Wen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.C. Chamberlain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.A. Grossman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.G. Cairncross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors
Report of the Quality Standards Subcommittee of the American Academy of Neurology
M.J. Glantz, B.F. Cole, P.A. Forsyth, L.D. Recht, P.Y. Wen, M.C. Chamberlain, S.A. Grossman, J.G. Cairncross
Neurology May 2000, 54 (10) 1886-1893; DOI: 10.1212/WNL.54.10.1886

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
14106

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

The Quality Standards Subcommittee seeks to develop scientifically sound, clinically relevant practice parameters for the practice of neurology. Practice parameters are strategies for patient management that assist physicians in clinical decision making. A practice parameter is one or more specific recommendations based on analysis of evidence on a specific clinical problem. These might include diagnosis, symptoms, treatment, or procedure evaluation. American Academy of Neurology (AAN) members have requested the publication of a practice parameter on the use of prophylactic anticonvulsants in patients with primary and metastatic brain tumors.

Justification.

Physicians often administer anticonvulsant medication prophylactically to patients with brain tumors, despite the lack of definitive evidence that prophylactic anticonvulsant therapy is effective in preventing first seizures.1-4 If anticonvulsant medications were free of side effects, their prophylactic use might be attractive even without such evidence. However, discomfort, expense, and inconvenience result from drug treatment and periodic monitoring of serum drug concentrations. Typical anticonvulsant-induced side effects, including cognitive impairment, myelosuppression, liver dysfunction, and dermatologic reactions (ranging from minor rashes to life-threatening Stevens–Johnson syndrome), appear to occur more frequently in patients with brain tumors than in other patient groups,3,5-16 although direct comparison studies have not been published. A spectrum of side effects unique to patients with brain tumors must also be considered. Phenytoin, carbamazepine, and phenobarbital reduce the efficacy of corticosteroids,17-21 which are administered almost universally to brain tumor patients. In addition, the ability of these anticonvulsants to stimulate the cytochrome P450 enzyme system results in markedly accelerated metabolism of a wide spectrum of chemotherapeutic agents including nitrosoureas, paclitaxel, cyclophosphamide, topotecan, irinotecan, thiotepa, 9-aminocampothecin, adriamycin, and methotrexate.22-34 As a result, inadequate chemotherapeutic dosing of brain tumor patients has been identified recently as a widespread and critically important problem.35 Conversely, corticosteroids and many chemotherapeutic agents alter the metabolism of anticonvulsants, making anticonvulsant under- and overdosing more common.35-45 The potential immunosuppressive effect of anticonvulsant medications represents an additional risk to this already immunocompromised patient population.46-49

In 1998, more than 170,000 patients were diagnosed with brain metastases, and more than 34,000 developed primary brain tumors.50-52 Twenty to 40% of all brain tumor patients have experienced a seizure by the time their brain tumor is diagnosed.3,4,11,12,14-16,53-61 In these patients, the need for anticonvulsant medication is clear. Patients who have not experienced a seizure remain at risk, however, and at least 20 to 45% more (depending on factors such as tumor histology, location, age, and treatment) will ultimately develop seizures.3,4,11-16,57-61 Because the number of newly diagnosed brain tumor patients is increasing yearly,62-65 the question of whether to administer prophylactic anticonvulsants is being posed to neurologists with increasing frequency by their patients and by colleagues in neurosurgery, internal medicine, oncology, and radiation oncology.

Although a number of studies have attempted to answer this question,3,11-14,56-60,66-68 these studies have used differing epidemiologic techniques, patient populations, treatment regimens, and outcome measures, and there remains no consensus among physicians about the optimum approach to this problem. Currently, the decision to administer prophylactic anticonvulsants to patients with brain tumors is based primarily on preference rather than clinical evidence, and varies by physician training and experience (table 1). Reliable guidelines, based on a critical review of the literature, are needed.

View this table:
  • View inline
  • View popup
Table 1.

Prophylactic anticonvulsant administration: physician practice in the state of Rhode Island by specialty

Description of process.

Pertinent studies were identified through MEDLINE searches of the years 1966 to July 1999 using the search parameters SEIZURE (exp), BRAIN NEOPLASMS (exp), ANTICONVULSANTS (exp), CRANIOTOMY (exp), and PRIMARY PREVENTION (exp). All 829 articles identified in this way were reviewed, and all studies, including randomized clinical trials, cohort studies, and case series, that considered the prophylactic use of anticonvulsants in patients with brain tumors were selected. The reference list of each of the selected papers was reviewed for additional pertinent studies. CANCERLIT and the Cochrane Database were also queried. Lastly, all abstracts indexed under “seizure,” “brain tumor,” or “anticonvulsant,” which appeared in the American Society of Clinical Oncology, American Academy of Neurology, American Neurologic Association, American Epilepsy Society, and American Association of Neurologic Surgeons abstract books between the years 1982 and 1999, were reviewed. When overlapping data were published more than once (for example, as a preliminary communication and subsequently, with additional patients, in final form) only the most updated version was selected. Two studies66,67 addressed the issue of prophylactic anticonvulsant use in patients with a variety of neurologic conditions, including patients with brain tumors, but neither the published data nor queries to the authors ultimately allowed separation of patients with brain tumors from those with other diagnoses. In a third study, prophylactic anticonvulsant medication was administered, and follow-up was carried out for only 3 postoperative days.68 These studies were excluded.

Studies included in the final analysis were then classified according to their level of evidence using published standards69,70 (Appendix). Reported seizure frequencies for patients in the anticonvulsant prophylaxis and nonprophylaxis groups in each study were compared by calculating odds ratios (ORs) and 95% confidence intervals (95% CIs). In two studies, the ORs were uninformative because none of the patients had seizures in either the anticonvulsant-treated14 or untreated12 groups (i.e., ORs of 0 and infinity respectively). For these two studies, reported seizure frequencies for patients in the anticonvulsant prophylaxis and nonprophylaxis groups were compared using Fisher’s exact test to accommodate studies with small numbers of seizures.

A meta-analysis was conducted on seizure incidence using all identified prospective, randomized clinical trials. Seizure-free survival (time to first seizure or death, whichever occurred first) and overall survival (time to death) were also calculated for the two studies from which patient-level data were available.15,16

For each end point in each trial, an OR, comparing the odds of the event in the anticonvulsant prophylaxis group relative to the control group, was computed. The trial-specific ORs were then averaged to provide a meta-analysis summary. The meta-analysis OR was used subsequently to test whether anticonvulsant prophylaxis affected the odds of an event. All statistical tests were performed using a Z test. Two-sided p values were used to compare the treatment groups with respect to the odds of an event. A p value less than 0.05 was considered significant.

For each clinical trial used in the seizure incidence analysis, the OR describing the odds of seizure in the anticonvulsant group relative to the control group was computed along with the variance (V) of log(OR), and a 95% CI for the OR estimate. These computations were performed using standard techniques.71 The meta-analysis OR was then obtained by computing the weighted average of the log(OR) estimates, for which the weightings were defined by the inverse variance (1/V) of log(OR) for each trial. In this way, each trial was weighted inversely according to the amount of variation associated with the log(OR) estimate. The standard error of the weighted average was obtained by dividing the sum of the weighting into one. The weighted average was then “exponentiated” to obtain the overall summary OR. Statistical inference was carried out on the log(OR) scale using normal (Z) distribution theory.71

The meta-analysis of seizure-free survival was performed using previously established techniques.72 For each clinical trial the Kaplan–Meier method73 was used to estimate seizure-free survival according to treatment group. The treatment comparison was then made using the logrank test,74 which evaluates the observed number of events (seizure or death) on each study arm compared with the number of events that would be expected to occur if each treatment group had the same risk. The logrank analyses were then averaged to obtain a meta-analysis comparison of the treatment groups in terms of an OR. The meta-analysis of overall survival was conducted in a similar fashion.

Results.

Twelve studies were identified that provided data on the frequency of first seizures in patients with brain tumors relative to the treatment of interest (prophylactic anticonvulsant use versus no prophylactic anticonvulsants). Of these, four were randomized clinical trials that provided level I evidence,15,16,60,61 and eight were cohort studies that provided level II evidence3,11-14,57-59 (table 2). One trial accrued patients from three participating centers16; the remainder were single-institution studies. Eleven of the 12 studies had no patients lost to follow-up. The remaining study61 reported 6 of 281 patients (2.1%) lost to follow-up, but this number includes all patients studied: 81 with brain tumors and 200 with other brain lesions. Specific numbers for the 81 brain tumor patients are not available. Median follow-up could be determined for six of the 12 studies: 5.44 months,16 7 months,15 8 months,14 14 months,59 14.5 months,12 and 19 months.11 In all studies, patients with previous seizures or prior use of anticonvulsant medication were excluded.

View this table:
  • View inline
  • View popup
Table 2.

Anticonvulsant prophylaxis studies in patients with brain tumors

Only one of the 12 studies58 reported a significant difference in seizure frequency between the anticonvulsant prophylaxis and nonprophylaxis groups, and this difference favored the nonprophylaxis group (i.e., a lower seizure frequency was seen in the nonprophylaxis group). A trend in favor of the nonprophylaxis group was seen in two of the four randomized studies, and three of the other seven nonrandomized studies. In the three studies (two randomized clinical trials15,16 and one cohort study3) that addressed this issue, no clinical or laboratory variable, including age, Karnofsky performance status, supratentorial tumor location, tumor histology, number of brain lesions, presence of hemorrhage, history of brain surgery, or pretreatment EEG was a significant predictor of first seizure occurrence.

Table 3 shows the seizure incidence and seizure-free survival results for each clinical trial considered in the meta-analysis, and for the meta-analysis summary. None of the trials provided statistical evidence of an effect of anticonvulsant prophylaxis on seizure incidence or seizure-free survival. The meta-analysis result confirms these findings, with an overall OR of 1.09 (95% CI, 0.63 to 1.89; p = 0.8) for seizure incidence and of 1.03 (95% CI, 0.74 to 1.44; p = 0.9) for seizure-free survival. There was also no effect of anticonvulsant prophylaxis on overall survival in the two trials that examined this question (p = 0.5 in one16 and p = 0.2 in the other15) or in the meta-analysis of overall survival (OR, 0.93; 95% CI, 0.65 to 1.32; p = 0.7).

View this table:
  • View inline
  • View popup
Table 3.

Meta-analysis results of seizure incidence and seizure-free survival in level I trials

Review of the 12 studies included in this analysis provided additional information pertinent to the issue of prophylactic anticonvulsant use in patients with brain tumors (table 4). Consistent with the literature, these studies recorded, in aggregate, a 26% incidence of seizures at or before brain tumor diagnosis (range, 14 to 51%), and a 19% incidence of seizures after brain tumor diagnosis (range, 10 to 45%). Seizures were more common, both before and after brain tumor diagnosis, in patients with primary compared with metastatic brain tumors. Of those seizures that occurred after brain tumor diagnosis, the initial seizure was a generalized tonic–clonic convulsion in 42% of patients (range, 10 to 77%). Among the eight cohort studies (in which prophylactic anticonvulsant use was determined by individual physician preference), 43% of patients received prophylaxis–63% of patients with primary and 32% of patients with metastatic brain tumors.3,11–14,57–59 In the seven studies in which drug levels were examined at the time of a seizure, 42% of patients receiving anticonvulsant prophylaxis had a subtherapeutic level3,12,14–16,59,60. In the six studies that recorded information on the frequency and severity of anticonvulsant side effects,11-16 23.8% of patients (range, 5 to 38%) experienced side effects severe enough to warrant a change in or discontinuation of anticonvulsant therapy. These side effects included rash (14%), nausea or vomiting (5%), encephalopathy (5%), myelosuppression (3%), and ataxia, increased liver enzymes, or gum pain (5%).

View this table:
  • View inline
  • View popup
Table 4.

Ancillary data from anticonvulsant prophylaxis studies in patients with brain tumors

Summary.

Twelve studies have examined, either in randomized controlled trials15,16,60,61 or cohort studies,3,11-14,57-59 the ability of prophylactic anticonvulsants to prevent first seizures in patients with brain tumors, and none have demonstrated efficacy. Four of these studies15,16,60,61 provide level I evidence. A meta-analysis of these four studies also revealed no evidence of an effect on the frequency of first seizures in patients receiving anticonvulsant prophylaxis. In contrast, deleterious interactions with cytotoxic drugs and corticosteroids are a major concern, and the incidence and severity of anticonvulsant side effects appear to be appreciably higher (20 to 40%) in brain tumor patients than in the general population of patients receiving anticonvulsants.6-16,75 This increased incidence is due at least in part to the additive or synergistic effects of concurrently administered drugs (especially chemotherapeutic agents) and to the underlying brain tumor.

Conclusions.

Seizures are a common and sometimes devastating complication of brain tumors, and meticulous attention to their diagnosis and treatment is critical. The available evidence suggests, however, that prophylactic administration of anticonvulsant medications does not provide substantial benefit (i.e., a risk reduction of 26% or more for seizure-free survival), whereas anticonvulsant-associated side effects are especially common and occasionally life-threatening.

Many patients who experienced seizures while receiving anticonvulsant prophylaxis had subtherapeutic anticonvulsant blood levels. Although this may provide one explanation for the ineffectiveness of anticonvulsant prophylaxis in some patients, it did not change the conclusions of the one randomized controlled trial that addressed that issue specifically.15 In that study, 23% of patients receiving anticonvulsant prophylaxis who experienced a seizure had subtherapeutic levels. Reanalysis excluding patients with subtherapeutic levels still showed no benefit for anticonvulsant prophylaxis. Moreover, even in the setting of scrupulously monitored prospective studies in epileptic patients, subtherapeutic levels are extremely common, partly because of drug interactions.76 Rather than change the implications of these studies, this high rate of subtherapeutic levels simply reflects a clinical reality.

The meta-analysis technique itself is not infallible. Its value depends on the quality of its component studies.77 A meta-analysis cannot evaluate or correct for bias in its component studies, and can provide misleading results if the component studies are very heterogeneous with respect to patient characteristics, the disease studied, or the intervention. The studies included in the current meta-analysis were all prospective, randomized, and controlled—the most effective strategy for minimizing the risk of bias and confounding. As described in the Description of process and Results sections, and as summarized in table 2, the studies were evaluated specifically to ensure good patient homogeneity. For these reasons, this meta-analysis does provide a reliable estimate of the overall lack of effect of anticonvulsant prophylaxis in patients with brain tumors.

Recommendations.

  • 1. In patients with newly diagnosed brain tumors, anticonvulsant medications are not effective in preventing first seizures. Because of their lack of efficacy and their potential side effects, prophylactic anticonvulsants should not be used routinely in patients with newly diagnosed brain tumors (standard).

  • 2. In patients with brain tumors who have not had a seizure, tapering and discontinuing anticonvulsants after the first postoperative week is appropriate, particularly in those patients who are medically stable and who are experiencing anticonvulsant-related side effects (guideline).

Future research.

Important clinical questions remain to be answered by future studies.

Are other anticonvulsants besides phenytoin, phenobarbital, and valproic acid effective in preventing first seizures in patients with brain tumors?

Phenytoin and phenobarbital are the most widely used anticonvulsants for seizure prophylaxis, and 11 of the 12 studies reviewed in this paper employed one or both of these agents either exclusively or primarily. One of the 12 studies (a prospective randomized trial) used valproic acid.15 These three anticonvulsants operate through different molecular mechanisms to prevent seizures, and together represent three primary mechanisms through which drug-mediated anticonvulsant effects are thought to be exerted. Prospective randomized studies would be required, however, to evaluate definitively the efficacy of the newer anticonvulsant medications in this setting.

Are there differences between specific subgroups of patients with brain tumors with regard to prevention of first seizures?

Some subgroups of patients with brain tumors (e.g., those with melanoma, hemorrhagic lesions, multiple metastases, tumors located near the Rolandic fissure, slow-growing primary brain tumors) have a higher risk of developing seizures.4,14,56,78-81 There is no evidence that anticonvulsant prophylaxis is more effective in any of these subgroups than in the population of patients with brain tumors as a whole, but prospective, randomized trials tailored specifically to these subgroups should be performed.

Does performance of a neurosurgical procedure influence the need for or the efficacy of prophylactic anticonvulsants in patients with brain tumors?

Most patients with primary brain tumors, and increasing numbers of patients with brain metastases, undergo a neurosurgical procedure (craniotomy or stereotactic biopsy) at the time of brain tumor diagnosis, and are placed on anticonvulsant medication during the perioperative period. Individual studies (including randomized clinical trials in patients with brain tumors) have either found no efficacy of prophylactic anticonvulsants at any point in the postcraniotomy setting or have shown a limited duration of benefit (no more than 72 days).15,16,61,67 Similarly, a meta-analysis of randomized clinical trials found no benefit for anticonvulsant prophylaxis in preventing postcraniotomy seizures in patients without preexisting seizures.82 Prophylactic anticonvulsants also fail to reduce the frequency of post-traumatic seizures beyond the first week after head injury.83-85 However, because of methodological shortcomings in the pertinent studies, including small numbers of patients in the brain tumor studies, additional corroborative studies are warranted.

What recommendations can be made about the safe operation of motor vehicles in patients with brain tumors?

Driving is a critical concern for patients, their families, and their physicians, and there are no data that address specifically the issue of anticonvulsant prophylaxis and suitability for driving in patients with brain tumors. Because of their lack of demonstrated efficacy in preventing first seizures, prophylactic anticonvulsants do not make driving any safer in patients who have never experienced a seizure. Frequently, neurologic deficits related to the tumor or its treatment, rather than the risk of seizures, constitute the primary barrier to safe operation of a motor vehicle. Legal considerations, which vary by state, will also influence recommendations regarding driving. Further research is needed.

Disclaimer.

This statement is provided as an educational service of the AAN. It is based on an assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurologic problem or all legitimate criteria for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved.

Appendix 1

Quality of evidence definitions

Class I: Evidence provided by one or more well-designed randomized, controlled clinical trials, including overviews (meta-analyses) of such trials

Class II: Evidence provided by one or more well designed observational studies with concurrent controls such as case–control or cohort studies

Class III: Evidence provided by expert opinion, case series, case reports, and studies with nonrandomized historical controls

Strength of recommendations

Standard: A principle for patient management that reflects a high degree of clinical certainty. Usually this requires class I evidence that addresses directly the clinical question, or overwhelming class II evidence when circumstances preclude randomized clinical trials.

Guideline: A recommendation for patient management that reflects moderate clinical certainty. Usually this requires class II evidence or a strong consensus of class III evidence.

Practice option: A strategy for patient management for which the clinical utility is uncertain because of inconclusive or conflicting evidence or opinion.

Appendix 2

American Academy of Neurology Quality Standards Subcommittee members: Gary Franklin, MD, MPH—Co-Chair; Catherine Zahn, MD—Co-Chair; Milton Alter, MD, PhD; Stephen Ashwal, MD; John Calverley, MD; Richard Dubinsky, MD; Jacqueline French, MD (facilitator); Michael Greenberg, MD; Gary Gronseth, MD; Deborah Hirtz, MD; Robert Miller, MD; and James Stevens, MD.

Acknowledgments

Acknowledgment

The authors thank Jacqueline French, MD for facilitating this project; the members of the Quality Standards Subcommittee for providing their expertise, time, and insight into the development of this document; and Wendy Edlund, the AAN Clinical Policy Administrator, for her patience and guidance in developing this practice parameter.

The authors and the subcommittee also thank the numerous individuals, AAN Sections, and organizations that reviewed drafts of this practice parameter, including the American Association of Neurological Surgeons, and the AB Baker, Child Neurology, Clinical Neurophysiology, Critical Care and Emergency Neurology, Epilepsy, Government Service, Interventional Neurology, Movement Disorders, Neuroepidemiology, Neurological Rehab, Neuro-Oncology, Pain, and Spine Sections of the AAN.

Footnotes

  • Approved by the Quality Standards Subcommittee October 9, 1999. Approved by the Practice Committee January 15, 2000. Approved by the AAN Board of Directors February 26, 2000.

  • Received November 30, 1999.
  • Accepted January 6, 2000.

References

  1. ↵
    Kvam DA, Loftus CM, Copeland B, et al. Seizures during the immediate postoperative period. Neurosurgery 1983;12:14–17.
    OpenUrlPubMed
  2. Deutschman CS, Haines SJ. Anticonvulsant prophylaxis in neurological surgery. Neurosurgery 1985;17:510–517.
    OpenUrlPubMed
  3. ↵
    Cohen N, Strauss G, Lew R, et al. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988;6:1621–1624.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Posner JB. Neurologic complications of cancer. Philadelphia:FA Davis, 1995.
  5. ↵
    Delattre J, Safai B, Posner JB. Erythema multiforme and Stevens–Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988;38:194–198.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Taylor LP, Posner JB. Phenobarbital rheumatism in patients with brain tumor. Ann Neurol 1989;25:92–94.
    OpenUrlPubMed
  7. Khe HX, Delattre JY, Poisson M. Stevens–Johnson syndrome in a patient receiving cranial irradiation and carbamazepine. Neurology 1990;40:1144–1145.
    OpenUrlFREE Full Text
  8. Borg MF, Probert JC, Zwi LJ. Is phenytoin contraindicated in patients receiving cranial irradiation? Australas Radiol 1995;39:42–46.
    OpenUrlPubMed
  9. Cockey GH, Amann ST, Reents SB, et al. Stevens–Johnson syndrome resulting from whole-brain radiation and phenytoin. Am J Clin Oncol 1996;19:32–34.
    OpenUrlPubMed
  10. Lehmann DF, Hurteau TE, Newman N, et al. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997;62:225–229.
    OpenUrlCrossRefPubMed
  11. ↵
    Mahaley MS, Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 1981;16:399–401.
    OpenUrlCrossRefPubMed
  12. ↵
    Hagen NA, Cirrincione C, Thaler HT, et al. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990;40:158–160.
    OpenUrlAbstract/FREE Full Text
  13. Hung S, Hilsenbeck S, Feun L. Seizure prophylaxis with phenytoin in patients with brain metastases. Proc Am Soc Clin Oncol 19991;10:A1151. Abstract.
  14. ↵
    Moots PL, Maciunas RJ, Eisert DR, et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995;52:717–724.
    OpenUrlCrossRefPubMed
  15. ↵
    Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996;46:985–991.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Forsyth PA, Weaver S, Fulton D, et al. A prospective randomized study of prophylactic anticonvulsants in patients with primary or metastatic brain tumors and without prior seizures. J Neurooncol 2000 (in press).
  17. ↵
    Haque N, Thrasher K, Werk E. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. J Clin Endocrinol Metab 1972;34:44–50.
    OpenUrlCrossRefPubMed
  18. Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 1984;25:119–123.
    OpenUrlPubMed
  19. Chalk JB, Ridgeway K, Brophy T, et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984;47:1087–1090.
    OpenUrlAbstract/FREE Full Text
  20. Dropcho EJ, Soong S. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41:1235–1239.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Wassner SJ, Malekzadem MH, Pennisi AJ, et al. Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol 1977;8:293–297.
    OpenUrlPubMed
  22. ↵
    Reich SD, Bachur NR. Alterations in adriamycin efficacy by phenobarbital. Cancer Res 1976;36:3803–3806.
    OpenUrlAbstract/FREE Full Text
  23. Warren RD, Bender AR. Drug interactions with antineoplastic agents. Cancer Treat Rep 1977;61:1231–1241.
    OpenUrlPubMed
  24. Gilbert MR, Grossman SA, Mikkelson T, et al. The impact of anticonvulsants on CPT-11 dose in patients with recurrent malignant glioma. Neurooncology 1999;1:313. Abstract.
    OpenUrl
  25. Levin VA, Stearns J, Byrd A, et al. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther 1979;208:1–6.
    OpenUrlAbstract/FREE Full Text
  26. Muller PJ, Tator CH, Bloom M. The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model. J Neurosurg 1980;52:359–366.
    OpenUrlPubMed
  27. Workman P, Bleehen NM, Wiltshire CR. Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer 1980;41:302–304.
    OpenUrlPubMed
  28. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity. Cancer Chemother Pharmacol 1990;27:226–228.
    OpenUrlCrossRefPubMed
  29. Baker DK, Relling MV, Pui C-H, et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992;10:311–315.
    OpenUrlAbstract
  30. Friedman AH, Ashley DM, Kerby T, et al. Topotecan treatment of adults with primary malignant glioma. Proc Am Soc Clin Oncol 1998;17:390A. Abstract.
    OpenUrl
  31. Chang TK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 1995;274:270–275.
    OpenUrlAbstract/FREE Full Text
  32. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 1997;15:3121–3128.
    OpenUrlAbstract
  33. Grossman SA, Hochberg F, Fisher J, et al. Increased 9-aminocampothecin dose requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 1998;42:118–126.
    OpenUrlCrossRefPubMed
  34. ↵
    Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of paclitaxel in patients with recurrent malignant gliomas: a North American Brain Tumor Consortium report. J Clin Oncol 1998;16:2188–2194.
    OpenUrlAbstract
  35. ↵
    Glantz MJ, Kim L, Choy H, Akerley W. Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncology 1999;13:78–82.
    OpenUrl
  36. Finchum RW, Schottelius DD. Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1979;1:277–283.
    OpenUrlCrossRefPubMed
  37. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982;7:57–84.
    OpenUrlCrossRefPubMed
  38. Sylvester RK, Lewis FB, Caldwell KC, et al. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 1984;6:302–305.
    OpenUrlCrossRefPubMed
  39. Neef C, de Voogd – van der Straaten J. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988;43:372–375.
    OpenUrlPubMed
  40. Jarosinski PF, Moslow JA, Alexander MS, et al. Altered phenytoin clearance during intensive treatment for acute lymphoblastic leukemia. J Pediatr 1988;112:996–999.
    OpenUrlCrossRefPubMed
  41. Grossman SA, Sheilder VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 1989;87:505–510.
    OpenUrlCrossRefPubMed
  42. Lackner TE. Interaction of dexamethasone with phenytoin. Pharmacotherapy 1991;11:344–347.
    OpenUrlPubMed
  43. Ghosh C, Lazarus HM, Hewlett JS, et al. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. J Neurooncol 1992;12:25–32.
    OpenUrlPubMed
  44. Rabinowicz AL, Hinton DR, Dyck P, et al. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995;36:513–515.
    OpenUrlCrossRefPubMed
  45. ↵
    Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann Pharmacother 1996;30:520–526.
    OpenUrlPubMed
  46. ↵
    Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine: studies in vivo and in vitro. Clin Exp Immunol 1975;20:273–285.
    OpenUrlPubMed
  47. Neuwelt EA, Kikuchi K, Hill S, et al. Immune responses in patients with brain tumors. Factors such as anti-convulsants that may contribute to impaired cell-mediated immunity. Cancer 1983;51:248–255.
    OpenUrlPubMed
  48. Bardana EJ, Gabourel JD, Davies GH, et al. Effects of phenytoin on man’s immunity: evaluation of changes in serum immunoglobulins, complement, and anti-nuclear antibody. Am J Med 1983;74:289–296.
    OpenUrlCrossRefPubMed
  49. ↵
    Kikuchi K, McCormick CI, Neuwelt EA. Immunosuppression by phenytoin: implications for altered immune competence in brain tumor patients. J Neurosurg 1984;61:1085–1090.
    OpenUrlPubMed
  50. ↵
    Davis F, Surawicz T, Barlas S, Propp J. Central Brain Tumor Registry of the United States. Chicago:CBTRUS, 1997.
  51. Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992;148:477–487.
    OpenUrlPubMed
  52. ↵
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–31.
    OpenUrlCrossRefPubMed
  53. ↵
    Simonescu MD. Metastatic tumors of the brain. A follow-up study of 195 patients with neurosurgical considerations. J Neurosurg 1960;17:361–373.
  54. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981;48:384–394.
    OpenUrlCrossRefPubMed
  55. Gilbert MR, Grossman SA. Incidence and nature of neurologic problems in patients with solid tumors. Am J Med 1986;81:951–954.
    OpenUrlCrossRefPubMed
  56. ↵
    Glantz M, Recht L. Epilepsy in the cancer patient. In: Vinken PJ, Bruyn GW, eds. Neuro-oncology. Part III. Neurological disorders in systemic cancer. Handbook of clinical neurology. Vol. 69. Amsterdam: Elsevier Publishing, 1997:9–18.
  57. ↵
    Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1:313–317.
    OpenUrlCrossRefPubMed
  58. ↵
    Dent S, Bociek G. Prophylactic anticonvulsants for cancer patients with newly diagnosed brain metastases. Proc Am Soc Clin Oncol 1996;15:529. Abstract.
    OpenUrl
  59. ↵
    Boarini DJ, Beck DW, VanGilder JC. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 1985;16:290–292.
    OpenUrlCrossRefPubMed
  60. ↵
    Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir 1990;103:47–51.
    OpenUrlCrossRefPubMed
  61. ↵
    North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 1983;58:672–677.
    OpenUrlCrossRefPubMed
  62. ↵
    Eby NL, Grufferman S, Flannelly CM, Schold SC, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer 1988;62:2461–2465.
    OpenUrlCrossRefPubMed
  63. Greig NH, Ries LG, Yanick R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990;82:1621–1624.
    OpenUrlAbstract/FREE Full Text
  64. Desmeules M, Middlesen T, Mao Y. Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. J Natl Cancer Inst 1992;84:442–445.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Devesa SS, Bot WJ, Stone BJ, et al. Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175–181.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    Matthew E, Sherwin AL, Welner SA, et al. Seizures following intracranial surgery: incidence in the first post-operative week. Can J Neurol Sci 1980;7:285–290.
    OpenUrlPubMed
  67. ↵
    Foy PM, Chadwick DW, Rajgopalan N, et al. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy. J Neurol Neurosurg Psychiatry 1992;55:753–757.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Lee S-T, Lui T-N, Chang C-N, et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 1989;31:361–364.
    OpenUrlCrossRefPubMed
  69. ↵
    Quality Standards Subcommittee of the American Academy of Neurology.Practice advisory: thrombolytic therapy for acute ischemic stroke—summary statement. Neurology 1996;47:835–839.
    OpenUrlFREE Full Text
  70. ↵
    American Society of Clinical Oncology Ad Hoc Non-Small-Cell Lung Cancer Expert Panel.Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997;15:2996–3018.
    OpenUrlAbstract
  71. ↵
    Rosner B. Fundamentals of biostatistics. 4th ed. Belmont, CA:Wadsworth, 1995.
  72. ↵
    Early Breast Cancer Trialists’ Collaborative Group.Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681–1692.
    OpenUrlCrossRefPubMed
  73. ↵
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
    OpenUrlCrossRef
  74. ↵
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1–39.
    OpenUrlCrossRefPubMed
  75. ↵
    Landau J, Baulac M, Durand G, et al. Impairment of consciousness induced by valproate treatment following neurosurgical operation. Acta Neurochir 1993;125:92–96.
    OpenUrlPubMed
  76. ↵
    Leppik IE. Compliance during treatment of epilepsy. Epilepsia 1988;29 (suppl 2):S79–S84.
  77. ↵
    Sacks HS, Berrier J, Reitman D, Ancona–Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450–455.
    OpenUrlCrossRefPubMed
  78. ↵
    Deutschman CS, Haines SJ. Anticonvulsant prophylaxis in neurological surgery. Neurosurgery 1985;17:510–517.
  79. Rasmussen T, Blundell J. Epilepsy and brain tumor. Clin Neurosurg 1959;7:138–158.
    OpenUrlPubMed
  80. Berger MS, Ghatan S, Haglund MM, et al. Low grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg 1993;79:62–69.
    OpenUrlCrossRefPubMed
  81. ↵
    Giles FA, Sobell E, Leviton A, et al. Epidemiology of seizures in children with brain tumors. J Neurooncol 1992;12:53–68.
    OpenUrlPubMed
  82. ↵
    Kuijlen JMA, Teernstra OPM, Kessels AGH, et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996;5:291–298.
    OpenUrlCrossRefPubMed
  83. ↵
    Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999;91:593–600.
    OpenUrlCrossRefPubMed
  84. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blinded study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323:497–502.
    OpenUrlCrossRefPubMed
  85. ↵
    Temkin NR, Haglund MM, Winn HR. Post-traumatic seizures. In: Youmans JR, ed. Neurological surgery. 4th ed. Philadelphia:WB Saunders, 1996:1834–1839.
View Abstract

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Justification.
    • Description of process.
    • Results.
    • Summary.
    • Conclusions.
    • Recommendations.
    • Future research.
    • Appendix 1
    • Appendix 2
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise